Mirum Pharmaceuticals, Inc. (MIRM) AI Stock Analysis

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies tailored for rare and orphan diseases that significantly impact patients' lives. Its lead product candidate is LIVMARLI, an investigational oral drug addressing critical unmet medical needs in progressive familial intrahepatic cholestasis disease, Alagille syndrome, and biliary atresia disease. The company is also advancing Volixibat for the treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018 and headquartered in Foster City, California, Mirum employs 433 people dedicated to expanding treatment options for liver-related disorders.

Mirum achieved a 5-year revenue CAGR of 116.3% from FY2020 through FY2025, with revenue climbing from $19.1M in FY2021 to $77.1M in FY2022, $186.4M in FY2023, $336.9M in FY2024, and $521.3M in FY2025. Gross margin stood at 80.7% in FY2025, while operating margin improved from -906.1% in FY2021 to -4.2% in FY2025. Annual net losses decreased from -$84.0M in FY2021 to -$23.4M in FY2025. For the trailing twelve months ended June 30, 2026, revenue totaled $618.1M with quarterly revenue growth of 37.9%, though trailing profit margin was -139.2% and EPS was -$14.10.

As of June 30, 2026, Mirum held $438.3M in cash and short-term investments alongside $760.5M in total debt, resulting in net debt of $322.3M. Total assets stood at $1.04B, liquidity remained supported by a current ratio of 2.86, and shareholders' equity was -$10.4M. In FY2025, operating cash flow reached $55.8M and free cash flow was $54.9M, while capital expenditures were $954,000. Additionally, the company's share count increased by 107.2% over a 5-year period.

Mirum holds a market capitalization of $5.20B and an enterprise value of $6.13B. The stock trades at a forward P/E of 166.7x, compared to the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple of 8.4x and EV/EBITDA of 341.2x also trade above peer group medians of 4.1x and 12.0x, respectively. Over the past year, Mirum gained 7.7%, trailing the 16.8% return of the S&P 500, but its 5-year gain of 368.1% outperformed the index return of 83.0%.

Mirum holds 10 Strong Buy ratings, 4 Buy ratings, and 0 Hold or Sell ratings. The mean price target is $153.07, representing a 91.0% premium over the closing price of $80.14. For the fiscal year ending December 31, 2026, analysts estimate revenue of $696.6M and an EPS of -$15.14. For the following fiscal year, consensus estimates point to revenue of $820.0M and EPS of -$0.72. The company exceeded EPS estimates in 1 of the last 4 quarters, with its next earnings release scheduled for November 3, 2026.

This page is an AI-written research summary of Mirum Pharmaceuticals, Inc. (MIRM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MIRM income statement, MIRM balance sheet, MIRM key metrics, MIRM analyst forecast, MIRM chart. See the MIRM stock overview for the latest quote and news.